



SHL/SEC/2026

February 06, 2026

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street,
Fort
Mumbai – 400 001.
Company Code: **537253**

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Dear Sir,

Sub. : **Outcome of the 266th Board Meeting held on 06.02.2026**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, that the Board of Directors of the Company at their Board Meeting held on Friday, February 06, 2026 interalia approved Un-Audited Financial Results (standalone and consolidated) for the 3rd quarter/ nine months ended December 31, 2025 of the FY 2025-26.

Copy of the approved Un-Audited Financial Results (standalone and consolidated) for the 3rd quarter/ nine months ended December 31, 2025 of the FY 2025-26 alongwith the Limited Review report thereon are enclosed herewith.

The Board meeting was started at 4:17 p.m. and **concluded at 5:55 p.m.**

You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,
for **Sunil Healthcare Limited**

Satyendu Pattnaik
Company Secretary & Compliance Officer
FCS-7736
Encl a/a

Sunil Healthcare Ltd.

38E/252-A, Vijay Tower, Opp Panchsheel Park Comm. Complex, New Delhi -110049

T: +91 -11-49435555/00, F: +91 -11-43850087 Email : info@sunilhealthcare.com, Web: www.sunilhealthcare.com

CIN No. : L24302DL1973PLC189662

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and nine months ended December 31, 2025. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Noida (Delhi-NCR)
Date: February 06, 2026

For Singhi & Co.
Chartered Accountants
Firm Reg. No. 302049E


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 26088926POPETN4861

Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sunil Healthcare Limited ("the Company/ the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following foreign subsidiaries:
 - a) Sunil Healthcare Mexico Sa De CV
 - b) Sunil Healthcare North America LLC



5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the interim financial results of two foreign subsidiaries which are not required to be audited/reviewed under the law of respective countries of their incorporation, whose interim financial results reflect revenue from operation of Rs. Nil and Rs. Nil, net profit after tax of Rs. 14.27 lakhs and Rs. 97.43 lakhs and total comprehensive income of Rs. (2.82) Lakhs and Rs. 4.83 lakhs for the quarter and nine months ended December 31, 2025 respectively, as considered in the statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.


For Singhi and Co.
Chartered Accountants
Firm Reg. No. 302049E




Bimal Kumar Sipani
Partner

Place: Noida (Delhi-NCR)
Date: February 06, 2026

Membership No. 088926
UDIN: 26088926NZPFPX4230



SUNIL HEALTHCARE LIMITED


Registered Office:
38E/252A, Vijay Tower, Shahpurjat
New Delhi-110049
CIN: L24800DL2019PTC000001
Email: info@sunilhealthcare.com
Website: www.sunilhealthcare.com

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2025

Particulars	Standalone				Year Ended Standalone 31st March 2025	Consolidated				Rs. in Lakhs Year Ended Consolidated 31st March 2025
	Quarter ended		Nine Months Ended			Quarter ended		Nine Months Ended		
	31st December 2025	30th September 2025	31st December 2024	31st December 2025		31st December 2024	30th September 2025	31st December 2024	31st December 2025	
1. Revenue from Operations	2,183.73	2,351.76	2,046.43	6,221.75	8,342.11	2,183.73	2,351.76	2,046.43	6,221.75	8,342.11
2. Other Income	35.28	21.02	55.04	84.76	135.17	49.76	42.06	53.04	177.63	133.91
3. Total Income (1+2)	2,219.01	2,372.78	2,101.47	6,306.51	8,477.28	2,233.49	2,393.82	2,099.47	6,400.38	8,476.02
4. Expenses										
a) Cost of Materials consumed	862.52	863.60	997.33	2,865.26	3,849.78	862.52	863.60	997.33	2,865.26	3,849.78
b) Purchase of Stock-in-trade	31.18	0.11	2.20	12.90	15.80	11.18	0.11	2.20	12.90	15.80
c) Changes in inventories of finished goods, work-in-progress, and stock-in-trade	(68.46)	(53.19)	(151.10)	(124.16)	(199.46)	(68.46)	(53.19)	(151.10)	(123.35)	(198.65)
d) Employees benefit expenses	324.76	332.15	294.59	977.10	1,179.58	324.76	332.15	294.59	977.10	1,179.58
e) Finance Costs	166.11	139.58	188.83	450.05	646.11	166.11	139.58	188.83	450.05	646.11
f) Depreciation and amortisation expense	161.61	164.26	168.54	492.03	635.43	161.61	164.26	168.53	492.03	635.49
g) Other Expenses	691.28	816.69	590.39	2,176.94	2,309.44	691.54	816.94	633.13	2,177.68	2,469.48
h) Total Expenses	2,149.00	2,263.20	2,090.78	6,658.81	8,436.68	2,149.26	2,263.45	2,133.51	6,659.55	8,597.59
5. Profit before tax (3-4)	70.01	109.58	10.69	23.08	40.60	84.23	130.37	(34.04)	317.77	(121.57)
6. Tax Expenses (Net)	25.71	30.68	20.01	27.97	20.09	25.71	30.68	20.01	27.97	20.09
a) Current Tax	12.19	26.73	4.21	9.97	8.94	12.19	26.73	(5.76)	51.05	18.94
b) Deferred Tax Charged/(Credit)	13.52	3.95	0.85	3.05	(3.80)	13.52	3.95	0.85	17.73	(3.80)
7. Profit/(loss) after tax	44.30	78.90	(9.32)	15.11	19.51	58.52	99.69	(54.05)	248.99	(14.95)
8. Other Comprehensive Income (OCI)	(12.71)	(12.71)	(12.71)	(38.15)	(59.35)	(12.71)	(12.71)	(12.71)	(38.15)	(59.35)
a) Items that will not be reclassified to Profit or Loss (net of tax)	(12.71)	(12.71)	(12.71)	(38.15)	(59.35)	(12.71)	(12.71)	(12.71)	(38.15)	(59.35)
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	-	-	-	-
9. Total Comprehensive Income	31.59	66.18	(22.03)	(43.04)	(19.84)	45.81	86.98	(66.76)	210.84	(74.29)
10. Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11. Other Equity (excluding revaluation reserve)	-	-	-	-	-	-	-	-	-	-
12. Earning per share of Rs.10/- each(not annualised)	0.43	0.77	(0.09)	(0.05)	0.20	0.57	0.97	(0.53)	2.43	(1.38)
(a) Basic (Rs.)	0.43	0.77	(0.09)	(0.05)	0.20	0.57	0.97	(0.53)	2.43	(1.38)
(b) Diluted (Rs.)	-	-	-	-	-	-	-	-	-	-

- These financial results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- As the Company's business falls within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.
- The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz. the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact of the aforesaid changes on the basis of the information available, consistent with the guidance issued by the Institute of Chartered Accountants of India, and has concluded that there is no impact on the standalone financial results of the Company for the quarter and nine months ended December 31, 2025. Accordingly, no adjustments have been recognised in the standalone financial results. Once the Central and/or State Rules are notified by the Government on all aspects of the Codes, the Company will evaluate any consequential impact, if any, on the measurement of employee benefits and provide appropriate accounting treatment in accordance with applicable accounting standards.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 06, 2026.

Place: NEW DELHI
Date: 06-02-2026



Anil Khaitan
(Chairman cum Managing Director)
DIN: 00759951

mailan